Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Ovarian Neoplasms 7Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Carcinoma 4Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma 2Hemangiosarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × trebananib × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Amgen

Phase 1 Completed
65 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00511459 2015-10-29

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Amgen

Phase 2 Completed
228 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡